![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EMA Spells Out Fast-Track Review Timing for COVID-19 Products
EMA Spells Out Fast-Track Review Timing for COVID-19 Products
The European Medicines Agency (EMA) said it will cut the review time for potential COVID-19 treatments and vaccines from 210 days to less than 150 days.
The agency also said it will review pediatric investigation plans related to COVID-19 products in 20 days, a significant reduction from the standard review time of 120 days.
In reviewing marketing authorizations for COVID-19 products, the EMA will use a rolling review process, used in emergency situations to evaluate early data for a drug. The agency is using this process to evaluate Gilead’s remdesivir (DID, May 4).
The emergency processes will remain in place until the pandemic ends, the EMA said.
Upcoming Events
-
18Jul
-
21Oct